AACR 2023: Therapeutic potential of polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma
In our latest AACR poster, WuXi AppTec scientists characterize the therapeutic potential of the antibody-drug conjugate (ADC) polatuzumab vedotin across a panel of established, in-house diffuse large B-cell lymphoma (DLBCL) patient-derived xenograft (PDX) models. Among our panel of lymphoma PDX models, three represent the germinal center B-cell (GCB) subtype. The authors show that 50% of these models are sensitive to polatuzumab vedotin treatment following just a single 2 mg/kg dose.
4673_Therapeutic potential of polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma_final - Copy